Ila Bappa Ibrahim: Bringing Sickle Cell Innovation Closer to Communities
Ila Bappa Ibrahim, Founder at Moobili, shared Safiyya Sickle Cell Foundation’s post on LinkedIn:
”It was an honor to represent the Safiyya Sickle Cell Foundation at the 50th NSHBT Official Annual General Meeting and Scientific Conference in Abuja.
Scientific innovations and precision medicine must never remain confined to high level discussions or elite settings.
If advanced care does not reach the grassroots through early diagnosis, accessible newborn screening, affordable care, and sustained health education, our mission is incomplete.
It was wonderful connecting with dedicated colleagues, advocates, and partners who share this vision.
Putting patients and communities at the absolute center of every conversation will always be our compass.”
Safiyya Sickle Cell Foundation shared a post on LinkedIn:
”Bringing the Patient and Community Voice to the National Conversation on Haematology
The Safiyya Sickle Cell Foundation (SSCF) was represented at the 50th Annual General Meeting and Scientific Conference of the Nigerian Society for Haematology and Blood Transfusion (NSHBT), held from 9–11 September 2026 at the Nigerian Army Conference Centre and Suites, Asokoro, Abuja.
Representing SSCF, our Project Manager, Ila Bappa Ibrahim, participated from a patient advocacy, community, and implementation perspective under the theme:
‘Haematology in the Era of Precision Medicine: Equity, Access and Implementation.’
His contribution highlighted an important question: How do we ensure that advances in medical science translate into real and accessible benefits for patients and families?
He highlighted the importance of early diagnosis and newborn screening, health literacy, patient counselling, affordability, access to treatment, continuity of care, and the role of community and patient organisations in bridging the gap between healthcare systems and the communities they serve.
A key message was that precision medicine should not end with a precise diagnosis.
Patients and families must also be able to understand their diagnosis, access appropriate care, and remain connected to the healthcare system.
The conference also provided opportunities to connect with stakeholders working across sickle cell advocacy, healthcare, media, and patient support, including Amr El-Sayed of Novo Nordisk, Senemi Aminah, and Obi Light Ogbonnia of the Obi Ogbonnia Sickle Cell Foundation (OOSCF).
For SSCF, participation in platforms like this reinforces our commitment to ensuring that the voices, experiences, and needs of patients and communities remain part of conversations shaping the future of sickle cell care in Nigeria.
From scientific advancement to meaningful impact, the patient must remain at the centre.”
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 10:08Ibrahim Mansoor: Rare Tests, Common Diseases – Rethinking Autoimmune Diagnostics
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils